Login
$MAZE
$33.58 -$0.75 (2.18%) Live

$MAZE 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027

16 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This letter agreement (this “Agreement”) confirms the agreement of Maze Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stoc...

17 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience

11 Aug 2026 8-K: Results of Operations and Financial Condition

Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027

10 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 8, 2026, Maze Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). 44,660,029 shares of common stock, representing approximately 89.75% of the total outstanding shares entitled t...

22 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the “Company”), effective June 1, 2026. Ms. Bachrodt’s resignation was not as a result of any disagreement with ...

12 May 2026 8-K: Results of Operations and Financial Condition

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027

22 Apr 2026 8-K: Other Events

Pre-Funded Warrants to Purchase 850,000 Shares of Common Stock

25 Mar 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT

04 Feb 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

On February 4, 2026 (the “Closing Date”), Maze Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Hercules Loan Agreement”), by and among the Company, as borrower, the lenders from time to time...

06 Nov 2025 8-K: Results of Operations and Financial Condition

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026

06 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Sep 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 10, 2025, by and among Maze Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreemen...

02 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 2, 2025, Maze Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Misbah Tahir as the Company’s Chief Financial Officer and “principal financial officer,” effective...

12 Aug 2025 8-K: Results of Operations and Financial Condition

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025

14 May 2025 8-K: Results of Operations and Financial Condition

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026

31 Mar 2025 8-K: Results of Operations and Financial Condition

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support